Over a 30 month period from 1987 to 1990, selective hepatic cannulation under fluoroscopic control was performed in 57 consecutive patients with primary and secondary malignancies of the liver. Fifty-three patients were subsequently treated using intra-arterial Lipiodol emulsified with epirubicin. The tumours treated were hepatocellular carcinoma (n 35), metastatic adenocarcinoma (n 14), intrahepatic cholangiocarcinoma (n 3) and leiomyosarcoma (n 1). For hepatocellular carcinoma the cumulative survival was 38% at one year; the median survival was 12.2 months for Stage I, 6.3 months for Stage II and 0.9 months for Stage III tumours.
INTRODUCTION
Primary liver cancer or hepatocellular carcinoma (HCC) is one of the commonest and most malignant tumours in the world. It is especially prevalent in South-east Asia and Japan, where it ranks second only to stomach cancer, and in Sub-saharan Africa1, where the incidence may be as high as 100 cases per 100,000 males per year2. Whilst the incidence is increasing in the United Kingdom3, it remains far below that of secondary liver tumours which complicate one third of all extrahepatic malignant disease. This is particularly true for colorectal cancer, where 20% of patients have multiple liver metastases at the time of their initial surgery. Up to 50% of all patients who present with colorectal carcinoma will eventually develop liver deposits, but in many cases the liver is the only site of recurrent disease following a successful resection of the primary tumour4. The treatment of choice in both primary hepatocellular carcinoma and metastatic disease is surgical resection, but this is possible in less than a quarter of patients1'4'5.
The prognosis is bleak in those patients with irresectable hepatic disease. Systemic chemotherapy and radiotherapy have a relatively low therapeutic index, 224 J. R. NOVELL ET AL. resulting in toxic side effects which are often unacceptable to the patient. This is partly a result of the high doses which are necessary to produce effective levels in tumour tissue.
Lipiodol Ultra-Fluid (May & Baker, England) is a lipid compound containing 475 mg of iodine per ml derived from poppyseed oil: it has been used for many years as a lymphographic contrast medium. When injected into the hepatic artery it is selectively retained in foci of hepatic tumour.In 1983 (Okuda, 1985) .
Of the 14 metastatic adenocarcinomas of gut origin, 10 Since epirubicin is not lipid-soluble, the drug was dissolved in 10ml of 60% sodium meglumine diatrizoate (Urografin 290). This solution was then mixed for 5 mins with 10ml of Lipiodol using a Pulsatron ultrasonic agitator (Kerry Ultrasonics Ltd, England). The resulting stable colloidal emulsion was selectively infused into the hepatic artery via a catheter inserted into the femoral artery.
ACT scan of the liver was performed 10 days after each treatment when the Lipiodol had cleared from the non-neoplastic liver parenchyma. Deposits of HCC were typically hypervascular and showed a dense, even distribution of the lipid (Figure 2 ), whereas uptake by metastases was less reliable and more commonly at the periphery of the tumour ( Figure 3 ). The three patients with cholangiocarcinoma had characteristically hypovascular tumours and showed poor uptake of the Lipiodol emulsion. 
RESULTS

Survival
Hepatocellular carcinoma Four patients who underwent surgery within 2 months of their first treatment were excluded from analysis. Three of these had attempted resection of the tumour, all of whom succumbed to postoperative complications associated with their cirrhosis. One patient underwent liver transplantation and has subsequently died of recurrent disease.
Thirty one patients with HCC are evaluable: all have been followed for a minumum of 6 months from the start of treatment. Nineteen patients have died from progression of their tumour, and two from unrelated conditions. The cumulative survival at one year was 38% with a median survival of 6.0 months from LIPIODOL CHEMOTHERAPY OF LIVER TUMOURS 
Secondary tumours
One patient underwent a successful resection of his tumour following the first treatment, and was excluded from analysis. Thirteen patients with metastatic adenocarcinoma are evaluable. Five patients are surviving between 6 and 13 months from the start of treatment, and eight died from tumour progression. The cumulative survival at 1 year was 63% ( Figure 5 ), and the median survival was 11.0 months from diagnosis (range 0.5-27 months). Excluding those cases treated with systemic chemotherapy the median survival was 10 months (range 0.5-13 months).
The patient with metastatic leiomyosarcoma is alive and well five months following Lipiodol-epirubicin treatment.
Cholangiocarcinoma
The three patients with intrahepatic cholangiocarcinoma died from tumour progression at 4.2, 12.3 and 20.9 months from diagnosis. Although up to one third of patients show a partial response to systemic chemotherapy, the benefit is often short-lived and there is no good evidence that it increases survival even if given by regional perfusion15. The possibility of specifically targeting therapy to tumours has thus been greeted with enthusiasm, particularly in Japan where Lipiodol "chemoembolisation" is now the first line treatment for inoperable hepatocellular carcinoma. Lipiodol-targeted chemotherapy has also been employed in tumours of the lung, gallbladder and pancreas 16 and of the bladder17.
The precise mechanisms of Lipiodol retention remain speculative. In particular, there is much debate as to whether this is an embolic phenomenon, with the Lipiodol being trapped in the microvasculature of the tumour circulation, or uptake by a population of tumour cells. In vivo microscopy of the liver following Lipiodol injection has shown active uptake of the lipid by cells of the reticulo-endothelial systemTM. The lipid is cleared from normal liver within a few days, possibly by shunting into the hepatic veins via the sinusoids.
The technique of "chemoembolisation" requires a limited number of feeding vessels which constitute the sole or principal arterial supply to a tumour, and in this respect the liver is particularly well suited anatomically. Another advantage of targeted chemotherapy in liver tumours is the very low incidence of associated toxicity. This is partly due to the efficiency of the liver macrophages in "scavenging" oily emulsionsTM, and partly a function of the high first-pass metabolism of cytotoxics such as epirubicinI9. These factors result in lower plasma levels of the drug and few systemic side effects, as this study confirms. In contrast, over 50% of patients receiving systemic chemotherapy with epirubicin exhibit symptoms of immediate and early toxicity including leucopaenia, alopaecia and vomiting2.
Despite previous reports to the contrary8'9, it is not our experience that Lipiodol-targeted chemotherapy results in either tumour shrinkage or reduction in levels of circulating markers. In terms of conventional response criteria, therefore, no response was seen in any patient. However, in about half of the cases studied a plateau in tumour growth was observed, in association with continued clinical wellbeing, for periods of between 4 and 21 months. No data is available on the stability of the Lipiodol-epirubicin emulsion within tissues, but it seems reasonable to postulate that the Lipiodol-epirubicin emulsion acts as a slow release preparation, inhibiting local tumour growth. Alternatively, tumour necrosis resulting from the treatment may not be evident on hepatic imaging. In theory the use of a more effective cytotoxic "warhead" such as the isotope Iodine-131 would result in The combination of arterial embolization, infusion chemotherapy, and chemoembolization has also been attempted to achieve maximal tumor response. Chemoembolization theoretically, results in ischemia, increased capillary permeability and an increased contact time between the cytotoxic agent and the tumor cells. This has been performed in several fashions: (1) embolization of one lobe and infusion of the non-embolized lobe, (2) sequential embolization and infusion of the same lobe, (3) chemoembolization using chemotherapeutic drugs mixed with arterial occlusive particulates, (4) Although the microcirculation of human liver might not be exactly similar to that of the rat liver, the presence of arterioportal shunting is alike. Chemoembolization of human liver using oily substance results in combined arterial and portal embolization, or total hepatic parenchymal and tumoral embolization. However, due to fast clearance of Lipiodol from the normal sinusoids within several hours to days and prolonged existence of Lipiodol within the tumor for weeks to months, most patients have tolerated Lipiodol chemoembolization without significantly higher complications than those who received other embolization methods. Because of the total hepatic embolization nature of Lipiodol chemoembolization intentional segmental infarction of the liver had been achieved by this method1. It is imperative that for palliative control of hepatic neoplasm not be excessive and only segmental or lobar hepatic embolization, instead of total hepatic embolization, is performed at one setting.
